MARLBOROUGH, Mass., June 10, 2026--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy ...
MARLBOROUGH, Mass., Dec. 8, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective ...
– Partnership with the NCI will build on the promising preliminary clinical activity of enzomenib in acute leukemia to further explore potential activity in other cancers – MARLBOROUGH, Mass., April ...
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research ...
New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical activity in various leukemia subtypes driven by ...
The phase 2 monotherapy study of enzomenib (DSP-5336) in the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement has enrolled the required number of patients for interim analysis ...
MARLBOROUGH, Mass., Dec. 9, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of nuvisertib, an investigational small molecule ...
New data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show promising clinical activity across a wide range of potentially therapeutic ...
Enzomenib was escalated from 40 mg twice a day (BID) to 400 mg BID with no dose-limiting toxicities (DLTs). Treatment-related adverse events (TRAEs) observed in at least 10% of patients were nausea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results